[Federal Register Volume 72, Number 106 (Monday, June 4, 2007)]
[Notices]
[Pages 30806-30807]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-10711]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of Federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Human and Avian Influenza Whole Genome Phage Display Libraries

    Description of Technology: Available for use in developing research 
reagents, therapeutics or diagnostics are recombinant bacteriophage 
display libraries for identifying influenza viral gene products in 
preparation for pandemic threats the cross-reactivity and long-term 
protection of interpandemic influenza vaccines. Influenza vaccines 
predominantly include haemagglutinin (HA) and Neuraminidase (NA) 
antigens that characterize annual circulating influenza types A and 
type B. Analyses of the immune responses against new candidate vaccines 
is required in order to identify the best correlate of protection 
against seasonal human influenza strains and potential pandemic 
strains.
    These ``Whole Viral Genome Phage Display Libraries'' express 
complete sets of protein fragments encoded by several Human and Avian 
Influenza strains including HlN1, H3N2, H5N1 and H7N7 and can be used 
for in depth analyses of plasma samples from: (a) Individuals exposed 
to human influenza; (b) individuals exposed to avian influenza; (c) 
individuals vaccinated with traditional influenza vaccines; (d) 
individuals vaccinated with new generation vaccines against human and 
bird influenza viruses.
    Applications: Serological assays for surveillance of pandemic 
influenza outbreaks; Serological assays for distinguishing between 
exposure to human and bird influenza strains; Serological assays for 
diagnosing true infections in previously vaccinated individuals; Rapid 
analyses of immune sera from pre-clinical and clinical trials of novel 
influenza vaccines; Mapping of monoclonal and polyclonal antibodies 
against different influenza gene products; Identification of highly 
conserved ``protective'' epitopes for inclusion in future broadly-
reactive influenza vaccines (against either inter-pandemic or pandemic 
influenza strains); Studies of viral protein-protein, viral RNA-protein 
and viral-host protein interactions (viral pathogenesis studies).
    Market: Influenza diagnostics and vaccines.
    Development Status: Materials available as research tools.
    Inventors: Hana Golding, Ph.D. (FDA), Surender Khurana, Ph.D. 
(FDA).
    Patent Status: HHS Reference No. E-031-2007/0--Research Tool.
    Licensing Status: Available for licensing as a biological material.
    Scientific Contact: Hana Golding, Ph.D.; FDA/CBER/OVRR/DVP/LR; 9000 
Rockville Pike, Building 29B, Room 4N04, Bethesda, MD 20892; E-mail: 
[email protected]; Phone: 301/827-0784.
    Licensing Contact: Michael A. Shmilovich, Esq.; National Institutes 
of Health, Office of Technology Transfer; 6011 Executive Blvd., Suite 
325, Rockville, MD 20852; E-mail: [email protected]; Phone: 301/
435-5019; Fax: 301/402-0220.

Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted 
Sites (BORIS) Alternative Splice Forms

    Description of Technology: This technology identifies twenty five 
(25) new alternatively spliced transcripts of the BORIS gene. The 
transcripts lead to the expression of seventeen different protein 
isoforms with variable N- and C-termini encoded by BORIS gene locus. 
Differential expression levels of BORIS isoforms were observed in 
different cancers. While some BORIS alternative splice variants were 
expressed at different levels in all types of cancers,

[[Page 30807]]

other expressed forms are specific to particular cancer(s).
    Advantages and Applications: Simple, rapid, RT-PCR based diagnostic 
test to detect BORIS isoforms in cancer patients; Profiling of BORIS 
splice variants can be useful as a diagnostic tool for the detection of 
cancers; BORIS can be a therapeutic target antigen for 
immunotherapeutic and/or siRNA based treatments for cancer; BORIS can 
be used in combination with other established immunogens for 
immunotherapeutic treatment of several cancers.
    Market: Approximately 600,000 deaths from cancer related diseases 
are estimated in 2007. The technology, involving a differential 
expression of BORIS isoforms in cancer, can be useful for the 
diagnostics and treatment of several cancers having a potential market 
of more than 7 billion U.S. dollars.
    Development Status: The technology is currently in the pre-clinical 
stage of development.
    Inventors: Victor V. Lobanenkov et al. (NIAID).
    Patent Status: U.S. Provisional Application No. 60/841,342 filed 31 
Aug 2006 (HHS Reference No. E-117-2006/0-US-01).
    Licensing Status: Available for exclusive and non-exclusive 
licensing.
    Licensing Contact: Mojdeh Bahar, J.D.; 301/435-2950; 
[email protected].
    Collaborative Research Opportunity: The NIAID Laboratory of 
Immunopathology is seeking statements of capability or interest from 
parties interested in collaborative research to further develop, 
evaluate, or commercialize methods of cancer diagnostics and treatment 
based on detection of BORIS isoforms. Please contact Cecilia Pazman at 
[email protected] or (301) 451-3526 for more information.

    Dated: May 23, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E7-10711 Filed 6-1-07; 8:45 am]
BILLING CODE 4140-01-P